EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Reno-Protective Effects of SGLT2 Inhibitors in Patients With Diabetes Undergoing Percutaneous Coronary Intervention: Insights From the BMC2 Registry

S Nabeel Hyder iD, Milan Seth iD, David E Hamilton iD, Heidi Stoute, Edouard Daher, Joseph Chattahi, Bashar Samman, Vishal Gupta, Carlo Briguori iD, Michael Rudnick, Devraj Sukul iD, Hitinder S Gurm iD

Circulation: Cardiovascular Interventions · 2026

DOI: 10.1161/circinterventions.125.015645 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Circulation: Cardiovascular Interventions, 2026. Verfasst von S Nabeel Hyder und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, University of Michigan Medical School, Frankel Cardiovascular Center, Ann Arbor (S.N.H., M.S…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Percutaneous Coronary Intervention, Acute Kidney Injury, Contrast Media. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Chronic therapy with sodium-glucose cotransporter 2 inhibitors (SGLT2i) is associated with long-term reno-protective benefits. There are limited data on the benefits of these agents against the risk of contrast-associated acute kidney injury (CA-AKI). METHODS: The retrospective study population included all patients with diabetes enrolled in the Blue Cross Blue Shield of Michigan Cardiovascular Consortium Percutaneous Coronary Intervention registry, a clinical registry of all percutaneous coronary intervention (PCI) cases at nonfederal hospitals in the state of Michigan. Included patients underwent PCI between January 2022 and September 2023. Patients on dialysis and those without post-PCI serum creatinine measurements were excluded. SGLT2i users were compared with nonusers with respect to CA-AKI outcomes, defined as an increase in serum creatinine of ≥0.5 mg/dL following PCI. Outcomes were evaluated in a risk-adjusted, propensity-matched analysis. RESULTS: Among 13 804 patients with diabetes who underwent PCI, CA-AKI occurred in 3.8% (82/2186) of SGLT2i users versus 5.2% (602/11 618) of nonusers (odds ratio, 0.71; P =0.004). In propensity-matched, risk-adjusted analysis, the pre-PCI use of SGLT2i correlated with a lower incidence of CA-AKI (3.69% versus 4.68%; adjusted odds ratio, 0.72; P =0.027). The protective effect of SGLT2i was preserved among higher-risk subgroups. CONCLUSIONS: Among patients with diabetes who underwent PCI, preprocedural use of SGLT2i correlated with a lower risk of CA-AKI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsPercutaneous Coronary InterventionAcute Kidney InjuryContrast MediaDiabetes MellitusKidneyCoronary Artery DiseaseDiabetes Mellitus, Type 2HumansRegistriesRetrospective StudiesTreatment OutcomeFemaleRisk FactorsAgedMichiganMaleMiddle AgedRisk AssessmentProtective FactorsTime FactorsBiomarkersCreatinineBlue Cross Blue Shield Insurance Plans

Stichwörter der Autor:innen

acute kidney injurycreatinineincidencesodium-glucose cotransporter 2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 InhibitorsContrast MediaBiomarkersCreatinine

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, University of Michigan Medical School, Frankel Cardiovascular Center, Ann Arbor (S.N.H., M.S., D.E.H., H.S.G.).
  • Division of Cardiology, Henry Ford St John Hospital, Detroit, MI (H.S., E.D.).
  • Department of Cardiology, Corewell Health Beaumont Research Institute, Dearborn, MI (J.C.).
  • Division of Cardiovascular Medicine, McLaren Health, Port Huron, MI (B.S.).
  • Department of Cardiology, Beacon Kalamazoo Heart Institute, Kalamazoo, MI (V.G.).
  • Department of Cardiology, Mediterranea Cardiocentro, Naples, Italy (C.B.).

ORCID-Profile: S Nabeel Hyder, Milan Seth, David E Hamilton, Carlo Briguori, Devraj Sukul, Hitinder S Gurm

Zitieren

APA

Hyder, S. N., Seth, M., Hamilton, D. E., Stoute, H., Daher, E., Chattahi, J., Samman, B., Gupta, V., Briguori, C., Rudnick, M., Sukul, D., & Gurm, H. S. (2026). Reno-Protective Effects of SGLT2 Inhibitors in Patients With Diabetes Undergoing Percutaneous Coronary Intervention: Insights From the BMC2 Registry. Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.125.015645

Vancouver

Hyder SN, Seth M, Hamilton DE, Stoute H, Daher E, Chattahi J, et al. Reno-Protective Effects of SGLT2 Inhibitors in Patients With Diabetes Undergoing Percutaneous Coronary Intervention: Insights From the BMC2 Registry. Circulation: Cardiovascular Interventions. 2026. doi:10.1161/circinterventions.125.015645

BibTeX
@article{Hyder2026,
  author = {Hyder, S Nabeel and Seth, Milan and Hamilton, David E and Stoute, Heidi and Daher, Edouard and Chattahi, Joseph and Samman, Bashar and Gupta, Vishal and Briguori, Carlo and Rudnick, Michael and Sukul, Devraj and Gurm, Hitinder S},
  title = {Reno-Protective Effects of SGLT2 Inhibitors in Patients With Diabetes Undergoing Percutaneous Coronary Intervention: Insights From the BMC2 Registry},
  journal = {Circulation: Cardiovascular Interventions},
  year = {2026},
  doi = {10.1161/circinterventions.125.015645}
}
Kostenlos starten →